Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia

Authors

  • Andrew Mitchell,

    1. Western Australian Liver Transplant Service, Sir Charles Gairdner Hospital, Nedlands, Australia
    Search for more papers by this author
    • These authors contributed equally to this study.

  • Leon A. Adams,

    Corresponding author
    1. Western Australian Liver Transplant Service, Sir Charles Gairdner Hospital, Nedlands, Australia
    2. School of Medicine and Pharmacology, University of Western Australia, Nedlands, Australia
    • School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Verdun Street, Nedlands, W.A. 6009, Australia
    Search for more papers by this author
    • These authors contributed equally to this study.

    • Telephone: 618-9346-3228; FAX: 618-9346-3098

  • Gerry MacQuillan,

    1. Western Australian Liver Transplant Service, Sir Charles Gairdner Hospital, Nedlands, Australia
    2. School of Medicine and Pharmacology, University of Western Australia, Nedlands, Australia
    Search for more papers by this author
  • Jon Tibballs,

    1. Department of Radiology, Sir Charles Gairdner Hospital, Nedlands, Australia
    Search for more papers by this author
  • Rohan vanden Driesen,

    1. Department of Radiology, Sir Charles Gairdner Hospital, Nedlands, Australia
    Search for more papers by this author
  • Luc Delriviere

    1. Western Australian Liver Transplant Service, Sir Charles Gairdner Hospital, Nedlands, Australia
    Search for more papers by this author

Abstract

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease characterized by mucocutaneous and visceral telangiectasia. Hepatic involvement with vascular malformations may lead to portal hypertension, biliary ischemia, and high-output cardiac failure. Liver transplantation is indicated for life-threatening disease but carries significant risk from surgery and chronic immunosuppression. We report a case of a 47-year-old woman with HHT successfully treated with the vascular endothelial growth factor (VEGF) antibody bevacizumab. The patient was referred for consideration of liver transplantation because of hepatic HHT leading to high-output cardiac failure, diuretic resistant ascites, cholestasis, and malnutrition. As she was considered a high-risk candidate for transplantation, she underwent 6 courses of bevacizumab (5 mg/kg) over 12 weeks. A dramatic improvement in her clinical state was observed after 3 months with reversal of cholestasis, resolution of cardiac failure and ascites, and improvement in nutritional status with a 10% dry weight increase. Treatment induced a marked reduction in liver vascularity and halving of her liver volume from 4807 to 2269 mL over 6 months. This was associated with normalization of her cardiac output from 10.2 to 5.1 L/minute. Correspondingly, she ceased diuretic medications, returned to full-time work, and was delisted as a transplant candidate. She remains well 6 months after completing treatment. In conclusion, antagonism of VEGF receptors led to a dramatic regression of hepatic vascular malformations and reversal of high-output cardiac failure and complications of portal hypertension in this patient with HHT. Bevacizumab may potentially alleviate the need for liver transplantation in this group of patients. Liver Transpl 14:210–213. 2008. © 2008 AASLD.

Ancillary